1.10

2.65% -0.03

Spero Therapeutics Inc (SPRO)

Overview News Price History Option Chain Financials Discussions Forecast

Spero Therapeutics Inc stock is traded at $1.10, with a volume of 361.23K. It is down -2.65% in the last 24 hours and down -0.90% over the past month. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Previous Close:

$1.13

Open:

$1.14

24h Volume:

361.23K

Relative Volume:

0.77

Market Cap:

$64.06M

Revenue:

$54.77M

Net Income/Loss:

$15.24M

P/E Ratio:

4.5156

EPS:

0.2436

Net Cash Flow:

$7.24M

1W Performance:

-8.33%

1M Performance:

-0.90%

6M Performance:

-58.96%

1Y Performance:

-53.19%

1-Day Range:

$1.09

$1.17

1-Week Range:

$1.09

$1.22

52-Week Range:

$1.08

$3.08

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name

Spero Therapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

857-242-1600

Address

675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA

Employee

Twitter

@spero_tx

Next Earnings Date

2026-11-12

Latest SEC Filings

SPRO's Discussions on Twitter

Compare SPRO vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRO Spero Therapeutics Inc	1.10	64.06M	54.77M	15.24M	7.24M	0.2436
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Sep-23-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-01-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-21	Reiterated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Initiated	Evercore ISI	Outperform
Nov-05-19	Reiterated	H.C. Wainwright	Buy
Sep-09-19	Initiated	Janney	Buy
Feb-09-18	Initiated	Cantor Fitzgerald	Overweight
Nov-27-17	Initiated	BofA/Merrill	Neutral
Nov-27-17	Initiated	Oppenheimer	Outperform
Nov-27-17	Initiated	Stifel	Buy

View All

Spero Therapeutics Inc Stock (SPRO) Latest News

Oct 15, 2026

Spero Therapeutics grants 556,000 awards to new hires for Spero Therapeutics stock - ad-hoc-news.de

Oct 15, 2026

Oct 12, 2026

Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight - GlobeNewswire Inc.

Oct 12, 2026

Sep 25, 2026

Discover Spero Therapeutics Alongside Two Promising Penny Stocks - simplywall.st

Sep 25, 2026

Sep 14, 2026

Spero Therapeutics (NasdaqGS:SPRO) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 14, 2026

Sep 11, 2026

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Sep 03, 2026

New employees get stock awards at Spero, unlocking from 2027 - Stock Titan

Sep 03, 2026

Sep 02, 2026

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times

Sep 02, 2026

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - marketscreener.com

Sep 02, 2026

A biotech CEO will speak in New York Sept. 15. Spero will stream it. - Stock Titan

Sep 02, 2026

Sep 01, 2026

Spero Therapeutics stock gains on small-cap biotech interest - ad-hoc-news.de

Sep 01, 2026

Aug 29, 2026

Resilient Spero Therapeutics stock prepares up to $300 million shelf as Nasdaq price holds around $1 - ad-hoc-news.de

Aug 29, 2026

Aug 28, 2026

Spero Therapeutics Launches New ATM Program With Jefferies for Up to $100 Million - TradingView

Aug 28, 2026

Spero TherapeuticsMay Offer Up To $300 Million In SecuritiesSEC Filing - tradingview.com

Aug 28, 2026